2,4-Bis(4-chlorobenzoyl)-l-methylpyrrole (llc). A solution of 10.0 g (0.045 mol) of IC, 5.8 mL (0.045 mol) of 4-chlorobenzoyl chloride, and 6.05 g (0.045 mol) of AlCl₃ in 1,2-dichloroethane was stirred for 4 h at 25 °C and then heated under reflux for 16 h. Additional portions of 4chlorobenzoyl chloride (5.8 **mL)** and AlC13 (6.05 g) were added. The mixture was heated under reflux for **5** h. The mixture was poured into dilute HCl and extracted with $CHCl₃$. The CHCl₃ solution was decanted to separate the insoluble solid. The CHCl₃ solution was washed successively with *N_,N*. (dimethylamino)propylamine solution, dilute HCl, and NaHCO₃ solution and dried (MgSO₄). The solvent was evaporated in vacuo. The residue (16 g) was dissolved in a smaller quantity of CHCl₃, the insoluble solid removed by filtration, and the solvent evaporated. The residue was recrystallized from EtOAc to give 2.0 g (12% yield) of white solid: ¹H NMR (CDCl₃) δ 7.80–7.46 (9 H, m), 7.10 (1 H, d, *J* ⁼1.5 Hz), 4.05 (3 H, s); UV (MeOH) 6 254 nm **(e** 29600), 307 (21 300).

Anal. Calcd for $C_{19}H_{13}Cl_2NO_2$: C, 63.70; H, 3.65; N, 3.90. Found: C, 63.29; H, 3.76; N, 3.90.

4-Chloro-4'-methoxybenzophenone (12). A mixture of 0.5 $g(1.4 \text{ mmol})$ of 11c and 0.3 mL (2.8 mmol) of anisole was heated at 95 "C in 10 g of PPA. After 1 h, 0.15 **mL** of anisole was added. The mixture was heated for **5** h. It was poured into water and extracted with CH_2Cl_2 . The CH_2Cl_2 solution was washed with $NaHCO₃$ solution, dried (MgSO₄), and concentrated to dryness. The residue was chromatographed on silic-AR CC-4 with a hexaneCH3CCl3 step gradient **as** eluant. The first compound-bearing fraction, upon evaporation and recrystallization of the residue from MeOH, gave 0.091 g of 12 as a white solid: mp 125-126 °C (lit.¹⁹ mp 125 °C); IR (CHCl₃) ν_{max} 3005, 1650, 1600 cm⁻¹; mass spectrum, *m*/e 246, 245, 218, 210, 138, 134.

The second chromatographic fraction on TLC (SiO₂; EtOAccyclohexane, 1:2) corresponded to a mixture of 2c and llc.

Acknowledgment. The authors thank Ms. R. R. Acchione, **Mr.** M. S. Mutter, and Dr. H. R. Almond for analytical data. The assistance of Dr. Jeffrey Sterling is also gratefully acknowledged.

Registry No. la, 37496-06-3; lb, 62128-31-8; IC, 62128-32-9; Id, 62128-33-0; le, 932-16-1; If, 62128-36-3; 2a, 62128-30-7; 2b, 62128- 43-2; **2c,** 62128-44-3; 2d, 62128-45-4; 2e, 932-62-7; 2f, 62128-39-6; 3a, 1072-83-9; 3b, 13169-71-6; 4a, 1072-82-8; 4b, 62128-38-5; 5a, 1192- 58-1; 5b, 1003-29-8; 6a, 36929-60-9; 6b, 7126-39-8; 7,62128-28-3; **8,** 62128-48-7; 9,76010-94-1; llc, 76024-67-4; 12,10547-60-1; 4-ChlOrO-N,N-dimethylbenzamide, 14062-80-7; 1-methylpyrrole, 96-54-8; 1 **methyl-5-(4-methylbenzoyl)pyrrole-2-acetate Na,** 35711-34-3; 544 **chlorobenzoyl)-l,4-dimethylpyrrole-2-acetic** acid, 33369-31-2; 1,2,5 trimethylpyrrole, 930-87-0; 4-chlorobenzoyl chloride, 122-01-0; anisole, 100-66-3; N,N-dimethylbenzamide, 611-74-5.

(19) P. Peterson, *Am. Chem. J.,* 46, **339 (1913).**

Linearly Fused Isoquinolines. 3.' Positional Effect of Substitution on Trifluoroacetic Acid Equilibrium of Tetrazole-Azide Systems. Anomalous Behavior in

András Messmer* and György Hajós

Central Research Institute for Chemistry, Hungarian Academy of Sciences, H-1525 Budapest, Hungary

Received September 17, 1980

A new method for synthesis of heteroaromatic azides has been elaborated, and a series of substituted tetrazolo[1,5-b]isoquinoline derivatives has been synthesized. The effect of R_1 and R_4 substituents on the equilibrium between 3-azidoisoquinoline (lb) and tetrazol[1,5-b]isoquinoline (la) was investigated. Only a slight difference in influence of substituents in the opposite positions R_1 and R_4 was found. In contrast to earlier examples, the equilibria discussed here are shifted to the tetrazole form in TFA!

Recently we have reported^{1,2} that tetrazolo[1,5-b]isoquinoline **(la),** in contrast to its two angular isomers, **tetrazolo[5,1-a]isoquinoline** and tetrazolo[1,5-a]quinoline, forms an equilibrium with its isomeric azido compound, 2-azidoisoquinoline (lb) (Scheme I). The equilibrium constants, 0.2 and 1.3 in chloroform and dimethyl sulfoxide, respectively, seemed highly suitable values for investigation of slight shifts of the equilibrium caused by different substituents or solvents. Both carbon atoms neighboring the "fusion site" of the title system can be substituted. This system is ideal for study of substituent effects exerted by R_1 or R_4 on opposite sides of the tetrazole ring fusion.

For this purpose, suitable model compounds bearing the same substituents R_1 and R_4 have been synthesized. The method reported by us^1 for the parent ring system allowed

the preparation of 5-methyltetrazolo[1,5-b]isoquinoline $(6a)$.

Oxidation of 3-chloro-1-methylisoquinoline³ with *m*chloroperbenzoic acid led to N-oxide **3** which under relatively forced conditions afforded the hydrazino N-oxide compound **4.** The surprisingly stable 3-hydrazino-lmethylisoquinoline **(5)** was prepared by titanium tri-

⁽¹⁾ Part 2: Gy. Hajbs and A. Messmer, *J. Heterocycl. Chem.,* **15,463 (1978).**

⁽²⁾ Gy. Hajbs and A. Messmer, *J. Heterocycl. Chem.,* **13,882 (1976).**

⁽³⁾ A. Kametani et al., *Chem. Pharm. Bull.,* **15, 704 (1967);** *Chem. Abstr., 67,* **82074 (1967).**

a Abbreviations: $D =$ dimethyl sulfoxide; $C =$ chloroform; $T =$ trifluoroacetic acid. $b^{-1}H NMR$ chemical shifts, δ .

chloride reduction in high yield; its reaction with nitrous acid gave the methyl-substituted tetrazole-azide isomer pair **(6)** (Scheme 11).

This synthetic route was, however, not applicable to preparation of the isomer with the $CH₃$ group in the opposite position (R_4) and neither of the desired bromosubstituted derivatives could be obtained in this way.

Interestingly, we observed formation of tetrazolo $[1,5$ blisoquinoline (la) when **2,3-diaminoisoquinolinium** tosylate (10), prepared from 3-aminoisoquinoline (7) with O -tosylhydroxylamine (TSH),⁴ was reacted with nitrous acid. In general, reactions of N-aminoazinium salts with nitrous acid lead to cleavage of the NH₂ group; therefore, in our case formation of 3-aminoisoquinoline **(7)** would have been expected (Scheme 111).

This surprising formation of a tetrazole raised a mechanistic question. Did the N-amination (e.g., $7 \rightarrow 10$) take place on the ring nitrogen? If TSH were to attack the amino nitrogen atom, instead the tosylate salt of 3 hydrazinoisoquinoline would have formed. **This** salt, when treated with sodium nitrite, obviously should give the tetrazole.

This possibility was, however, excluded by comparison of the tosylate salt of 3-hydrazinoisoquinoline prepared from ethanolic solutions of 3-hydrazinoisoquinoline and

equivalent p-toluenesulfonic acid (mp 192 **"C)** with the crystalline product obtained from 3-aminoisoquinoline and TSH (10). Both infrared spectra and melting points showed that the two substances were different. The fact that diamino compound 10 could be recovered **from** acetic acid solution after 1 h excluded also the possibility of a rearrangement of 10 to the 3-hydrazino derivative.

Several other substituted 2,3-diaminoisoquinoline **salts** show the same behavior. Thus, diaminoisoquinolinium salts 11 and 12, prepared from 3-amino-1-bromoisoquinoline **(8)** and **3-amino-4-methylisoquinoline (9)** with TSH, reacted with nitrous acid to give the corresponding tetrazole-azide isomer pairs 13 and 14.

In the case of derivative 13 $(R_1 = Br)$, which, as will be shown below, exists entirely in azido form, the synthesis is to our knowledge the first preparation of an azido compound which involves ring opening of the isomeric tetrazole: the first **step** is necessarily the formation of tetrazole 13a which rapidly opens to azide 13b.

Preparation of the counterpart of 13, i.e., 15 $(R_4 = Br)$, was relatively easy. Bromination of the unsubstituted tetrazole la led selectively to 3-azido-4bromoisoquinoline (15b, Scheme IV), **as** shown unambiguously by ita NMR spectrum.

These five derivatives containing methyl or bromo groups as R_1 or R_4 were studied in CDCl₃, Me₂SO- d_6 , and trifluoroacetic acid solutions by NMR and, **as** solid crystals, by IR. Table I summarizes the characteristic *NMR* shifts,

⁽⁴⁾ E. **E. Glover** and K. **T.** Rowbottom, *J. Chem. Soc., Perkin* **Tram. 1,** 367 (1976).

Scheme V

the equilibrium constants determined on the basis of integration of singlet H_1 or CH_3 signals in the NMR spectra, and appearance of the solid-state azide band in the IR spectra.

Several features detailed in Table I are in good agreement with earlier publications: 5 (i) chemical shifts of the R_1 = H proton in tetrazoles have higher δ values relative to those in the corresponding azides due to the increased ring current; (ii) the electron-releasing methyl group enhances the stability of the tetrazole form, but the electron-attracting bromo atom favors the azido isomer; (iii) in every case the tetrazole form is favored in Me₂SO relative to the equilibrium constant in CDC13.

An interesting picture can be obtained by comparison of compound pairs in Table I, i.e., between derivatives having a certain substituent as R_1 or R_4 . The differences in K values caused by the position of $\rm CH_{3}$ or Br substituents seem to be rather slight. The most remarkable difference is that while 3-azido-1-bromoisoquinoline **(13b)** does not form any tetrazole at **all,** the 4-bromo equilibrium $(15a \rightleftharpoons 15b)$ is shifted to the tetrazole side $(15a)$ to a very small extent in $Me₂SO$ solution. This fact seems to be in agreement with the generally accepted explanation of the cyclization of azide to tetrazoles, namely, that the lone pair6 of the ring nitrogen favors ring closure. Therefore, the more remote the position of the substituent, the less pronounced the expected effect.

A surprising set of data was found in trifluoroacetic acid. According to the literature,' TFA shifts the equilibrium toward the azide isomer. We found, however, that the equilibrium **constants** obtained in TFA solutions are higher than those in CDC13. Methyl derivatives **6** and **14** do not contain any trace of azide component (Scheme V)!

This unusual behavior seems to be due to the linearly fused heteroaromatic ring rather than to any solvent effect. As we mentioned earlier' we believe that the relative instability of **tetrazolo[l,5-b]isoquinoline (la)** can be attributed to its quinonoid electronic structure. This disappears, however, when the neutral ring **is** protonated **(IC).** The essential energetic difference between the neutral and the protonated forms, which does not exist with the angularly fused tetrazoloquinoline or tetrazolo $[1.5-a]$ isoquinoline, may cause the apparent anomaly in TFA solutions.

Evidence for existence of a tetrazolium salt in TFA was supported by treatment of the TFA solution of **14** with HBF₄ and subsequently with ether. Compound 14c was obtained in crystalline form. NMR spectra of **14c** and **14** in TFA were identical.

Experimental Section

Melting **points** are uncorrected. IR spectra were recorded with Unicam SP 200 equipment. NMR spectra were obtained by Varian EM-360 apparatus.

3-Aminoisoquinoline,8 **l-bromo-3-aminoisoquinoline,8** 3 amino-4-methylisoquinoline,⁹ O-tosylhydroxylamine (TSH),⁴ and 3-chloro-1-methylisoquinoline² were synthesized according to literature procedures.

3-Chloro-1-methylisoquinoline 2-Oxide (3). **A** mixture of 0.5 g (2.7 mmol) of **3-chloro-1-methylisoquinoline (2),** 0.8 g (4.6 mmol) of m-chloroperbenzoic acid, and 8 mL of benzene was stirred until a solution formed and was allowed to stand at room temperature for 2 days. Treatment of the reaction mixture with sodium carbonate solution followed by extraction with dichloromethane afforded 0.35 g (65%) of crude product. Recrystallization from ethyl acetate yielded colorless crystale: mp 155-158 °C; NMR (CDCl₃) δ 8.2-7.3 (m, 5 H, H₄₋₈), 2.9 (s, 3 H, $CH₃$.

Anal. Calcd for C₁₀H₈ClNO (mol wt 193.64): C, 62.02; H, 4.16; N, 7.23. Found: C, 62.34; H, 4.50; N, 6.98.

3-Hydrazino-1-methylisoquinoline 2-Oxide (4). A mixture of 2.3 g (11.9 mmol) of 3-chloro-1-methylisoquinoline 2-oxide, 14 mL of *n*-butanol, and 14 mL of 100% hydrazine hydrate was refluxed for 1 h. The excess hydrazine hydrate was removed from the cold reaction mixture by extraction with water. Evaporation of the organic layer gave 1.7 g (76%) of crude product which, on recrystallization from ethanol-ether, resulted in yellow needles: 0.9 g (40%); mp 155–157 °C; IR (KBr) 3600–2900, 1660, 1640,
1570, 1520 cm⁻¹; NMR (TFA) δ 7.9–7.2 (m, 4 H, H₅₋₈), 7.1 (s, 1 H, H_4), 2.8 (s, 3 H, CH₃).

Anal. Calcd for C₁₀H₁₁N₃O (mol wt 189.22): C, 63.48; H, 5.86; N, 22.21. Found: C, 63.06; H, 6.02; N, 21.95.

3-Hydrazino-1-methylisoquinoline (5). 3-Hydrazino-lmethylisoquinoline 2-oxide (4,0.5 g, 2.6 mmol) was treated with 6 mL of 15% titanium trichloride solution at room temperature. The pH of the resulting solution was adjusted with sodium hydroxide to a value of 10. Extraction with dichloromethane gave 0.32 **g** (70%) of pale yellow crystals: mp 108-110 "C; mass spectrum, m/e 173 (M^+).

Anal. Calcd for C₁₀H₁₁N₃ (mol wt 173.22): C, 69.34; H, 6.40; N, 24.26. Found: C, 69.12; H, 6.63; N, 24.12.

5-Methyltetrazolo[1,5- b]isoquinoline (6). 3-Hydrazino-lmethylisoquinoline (0.4 g, 2.3 mmol) was dissolved in a mixture of 3 mL of water and 3 mL of acetic acid and was treated with a solution of 0.2 g of sodium nitrite (2.9 mmol) in 2 mL of water. A crystalline solid separated at once which, after further addition of water, was filtered and recrystallized from water-acetonitrile (50%) to yield 0.22 g (51%) of product, mp 123-124 "C.

Anal. Calcd for C₁₀H₈N₄ (mol wt 184.2): C, 65.20; H, 4.38; N, 30.42. Found: C, 64.87; H, 4.62; N, 30.16.

3-Azido-4-bromoisoquinoline (15). Tetrazolo[1,5-b]isoquinoline (0.51 g, 3.0 mmol) was dissolved in 5 mL of acetic acid and the solution was treated with 1.45 g (9.0 mmol) of bromine dropwise at room temperature. The reaction mixture was purified from the small tarry byproduct by filtration and the yellow fitrate was neutralized by sodium hydroxide solution. A cream-colored precipitate formed which was filtered and recrystallized from methanol to give 0.45 g of product (60%): mp 133-135 °C: NMR $(CDCI₃)$ δ 8.9 (s, H₁), 8.05 (m, H₅), 7.73 (m, H₆), 7.50 (m, H₇), 7.88

⁽⁵⁾ M. Tisler, Synthesis, 123 (1973). (6) L. A. Burke et al., J. Am. Chem. Soc., 98, 1685 (1976).

⁽⁷⁾ R. N. Butler, Adu. Heterocyel. Chem., 21, 402 (1977).

⁽⁸⁾ **F. Johnson and W. A. Nasutavicus, J.** *Org. Chem.,* **27,3953 (1962). (9) H. Win and H. Tickelman,** *J. Org.* **Chem., 32, 59 (1967).**

 (m, H_8) $(J_{5,6} = 8.4, J_{6,7} = 6.9, J_{7,8} = 8.0, J_{5,7} = 1.2, J_{6,8} = 1.6, J_{5,8}$ $= 0.6, J_{1,5} = 0.6$ Hz).

Anal. Calcd for $C_9H_5BrN_4$ (mol wt 249.09): C, 43.40; H, 2.02; Br, 32.08. Found: C, 43.19; H, 2.31; Br, 31.67.

Preparation of 2,3-Diaminoisoquinolinium Salts 10-12. A solution of the requisite 3-aminoisoquinoline derivative (5.0 mmol) in 10 mL of dichloromethane was treated with a solution of 5.2 mmol of 0-bsylhydroxylamine **in** 20 **mI,** of dichloromethane at 0-5 °C. The product precipitated in crystalline form within 10 min. A further quantity of the crystals deposited on addition of a limited amount ot ether. Recrystallization from isopropyl alcohol gave rise to brilliant yellow needles.

2,3-Diaminoisoquinolinium tosylate (10): mp 160-162 "C (65%); perchlorate salt, mp 170-172 °C; NMR (TFA) δ 9.1 (s, 1 H, H_1), 8.0–7.5 (m, 4 H, H_{5-8}), 8.45 (s, 1 H, H_4).

Anal. Calcd for $C_{16}H_{17}N_3O_3S$ (mol wt 331.40): C, 57.99; H, 5.17; S, 9.68. Found: C, 57.70; H, 5.40; S, 9.61.

2,3-Diamino-4-methylisoquinolinium tosylate (**12):** mp 168-170 "C (67%); fluoroborate salt, mp 182-184 *"C;* **NMR** (TFA)

 δ 9.1 (s, 1 H, H₁), 8.05-7.4 (m, 4 H, H₅₋₈), 2.65 (s, 3 H, CH₃). Anal. Calcd for C₁₇H₁₉N₃O₃S (mol wt 345.43): C, 59.11; H, 5.54;

S, 9.28. Found: C, 58.93; H, 5.80; S, 9.03. **l-Bromo-2,3-diaminoisoquinolinium tosylate (1 1):** mp 175-177 °C (45%).

Anal. Calcd for C₁₆H₁₆BrN₃O₃S (mol wt 410.31): C, 46.84; H, 3.93; N, 10.24; Br, 19.48. Found: C, 46.52; H, 3.98; N, 10.01; Br, 19.10.

Reaction of the Diaminoisoquinolinium Salts with Nitrous Acid. A solution of the **2,3-diaminoisoquinolinium** derivative (3.0 mmol) in a mixture of 10 mL of acetic acid and 10 mL of water

was treated with a solution of 0.35 g (5.1 mmol) of sodium nitrite in 3 mL of water at room temperature. Cryatalline precipitate deposited within few minutes which was fiitered and recrystallized from the given solvent.

Tetrazolo[l,5-b]isoquinoline (la). The product obtained by this procedure in 70% yield proved to be fully identical (spectroscopical data and physical constants) with that prepared by earlier methods.^{1,2}

10-Methyltetrazolo[1,5-b]isoquinoline (14): mp 139-141 "C (EtOH); yield 65%.

Anal. Calcd for $C_{10}H_8N_4$ (mol wt 184.21): C, 65.20; H, 4.38; N, 30.42. Found: C, 64.92; H, 4.51; N, 30.18.

3-Azido-1-bromoisoquinoline (13): mp 113-114 "C (MeOH); yield 60%.

Anal. Calcd for $C_9H_5BrN_4$ (mol wt 249.09): C, 43.40; H, 2.02; Br, 32.08. Found: C, 43.28; H, 2.34; Br, 31.72.

10-Methyltetrazolo[1,5-b]isoquinoline HBF, Salt (14c). A solution of **14** in TFA was treated with a few drops of hydrofluoroboric acid (40%) and ether was added. Colorless crystals separated which were recrystallized from nitromethane; mp $174-175$ °C.

Anal. Calcd for $C_{10}H_9BF_4N_4$ (mol wt 272.03): C, 44.15; H, 3.83; N, 20.60. Found: C, 43.87; H, 3.95; N, 20.31.

Registry No. la, 33459-64-2; **lb,** 60877-39-6; **2,** 15787-12-9; **3,** 75949-08-5; **4,** 75949-09-6; 5,75949-10-9; **6a,** 75949-11-0; **6b,** 75949 perchlorate salt, 75949-15-4; 11,75949-17-6; 12,75949-19-8; **12** flue roborate salt, 75949-20-1; **13,** 75949-21-2; **14a,** 75949-22-3; **14b,** 75949-23-4; **14c,** 75949-25-6; **15a,** 75949-26-7; **15b,** 75961-48-7. 12-1; **7,** 25475-67-6; 8, 13130-79-5; **9,** 7697-66-7; 10, 75949-14-3; **10**

Pyrimidines. 17. Novel Pyrimidine to Pyridine Transformation Reaction. One-Step Synthesis of Pyrido[2,3-d]pyrimidines1

Kosaku Hirota, Yukio Kitade, and Shigeo Senda*

Gifu College of Pharmacy, Mitahora-Higashi, Gifu 502, Japan

Michael J. Halat, Kyoichi **A.** Watanabe,* and Jack J. **Fox**

Sloan-Kettering Institute for Cancer Research, Sloan-Kettering Division of Graduate School of Medical Sciences, Cornell University, New York, New York 10021

Received October 6, 1980

A number of 2,6-dihydroxypyridines **(3)** and **pyrido[2,3-d]pyrimidines (9)** were prepared in one step from 1,3-dimethyluracil derivatives **(1)** via new transfragment reactions by which the $N_1-C_2-N_3$ fragment of 1 is displaced by the C-C-N fragment of acyclic or cyclic 1,3-ambident nucleophiles. As acyclic nucleophiles, acetamide derivatives (2) substituted at the α position with an electron-withdrawing R^3 group were employed. The products were 2,6-dihydroxypyridines substituted at C3 with R3 **(3). 1,3-Dimethyl-4-thiouracil (4)** could be converted into **2-hydroxy-6-mercaptonicotinamide (5)** by treatment with malonamide. 1-Methylpyridine derivatives **(6)** could be obtained by treatment of 1,3-dimethyluracil (1a) with N,N'-dimethylmalonamide or N-methylcyanoacetamide. Treatment of **la** with malononitrile in ethanolic NaOEt gave **3-cyanc-2-ethoxy-6-hydroxypyridine (7).** Derivatives of **1,3-dialkyl-6-aminouracil** (8) were used as cyclic 1,3-ambident nucleophiles. Treatment of 5-substituted 1,3-dimethyluracil (1) with **8** in base afforded **1,3-dialkyl-6-substituted-pyrido[2,3-d]pyrimidine-2,4,7-** (lH,3H,8H)-trione **(9).** Compound **4** was converted into **7-mercapto-l,3-dimethylpyrido[2,3-d]pyrimidine-2,4-** (1H,3H)-dione **(10)** by treatment with **1,3-dimethyl-6-aminouracil.** Treatment of **5-cyano-l,3-dimethyluracil (le)** with 1-n-butyl-6-aminouracil (11) afforded 1-n-butyl-6-cyanopyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione (12). Plausible mechanisms for the pyrimidine-to-pyridine and **pyrimidine-to-pyrido[2,3-d]pyrimidine** transformation reactions are proposed.

The synthesis of simple heterocyclic compounds has been approached in three different ways: (a) total synthesis by cyclization of acyclic compounds, (b) introduction **or** modification of functional groups on a heterocyclic ring, and (c) ring transformations of cyclic compounds.² For preparative purposes, the last method has rarely been employed. **For** example, uracil derivatives were converted into pyrazolone by treatment with hydrazine; 3 however,

⁽¹⁾ This investigation was supported by funds from the National **Cancer** Institute, US. Department of Health and Human Services Grants No. CA-OS748 and CA-18601.

⁽²⁾ For a comprehensive review of ring transformations, see: van der Plas, H. C. "Ring transformations of Heterocycles"; Academic Press: London and New York, 1973; Vol. 1 and **2.**